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background: EVEREST II is a prospective, multi-center, randomized controlled trial (RCT) to compare the safety and effectiveness of the MitraClip 
System with mitral valve (MV) surgery in the treatment of patients with severe (≥3+) MR. Patients with symptoms, or if asymptomatic with left 
ventricular (LV) dysfunction, pulmonary hypertension or atrial fibrillation were included. All patients will complete 5 year follow-up by December 
2013. We will report final EVEREST II RCT outcomes at 5 years to evaluate the durability of MR reduction, components of clinical endpoints, and LV 
volumes in MitraClip device and MV surgery patients. Outcomes by type of intervention and etiology and predictors of late success are of continued 
interest.
Methods: 279 patients, randomized 2:1 between MitraClip device (n=184) and MV surgery (n=95) were enrolled. The primary safety endpoint 
was the Major Adverse Event (MAE) rate at 30 days and the primary effectiveness endpoint was defined as freedom from the combined outcomes 
of death, MV surgery or re-operation for valve dysfunction, and MR >2+ at 12 months. Clinical outcomes of MR reduction, freedom from mortality, 
freedom from MV surgery or re-operation, LV volumes and NYHA Functional Class at 5 years will be presented.
results: The mean age was 67 years; baseline ejection fraction was 60%. MR etiology was degenerative in 73%. The 30 day primary safety and 
12 month primary effectiveness endpoints were previously reported. At 6 months, 19% of MitraClip patients underwent surgery. At 4 years, 78% of 
surviving MitraClip patients and 75% of surviving MV surgery patients had MR ≤ 2+. Kaplan-Meier freedom from MV surgery or re-operation was 
75% for MitraClip and 94% for MV surgery. Few MitraClip patients converted to MV surgery after 6 months. Both MitraClip and MV surgery patients 
experienced significantly reduced LV end diastolic volumes and improved NYHA Functional Class from baseline, demonstrating durability of MR 
reduction and associated clinical benefit with the MitraClip device.
conclusions: Detailed final 5 year results of the EVEREST II RCT will be presented to evaluate durability of outcomes post-treatment with both 
MitraClip and MV surgery.
